# **Summary of Product Characteristics**

#### **1 NAME OF THE MEDICINAL PRODUCT**

Lamictal 25 mg chewable/dispersible tablets

## **2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each Lamictal 25 mg chewable/dispersible tablet contains 25 mg lamotrigine.

For the full list of excipients, see section 6.1.

#### **3 PHARMACEUTICAL FORM**

Chewable/dispersible tablet.

Product imported from Spain and Germany:

White to off-white square tablet with rounded corners with a blackcurrant odour, marked "GSCL5" on one side "25" on the other. The tablets may be slightly mottled.

#### **4 CLINICAL PARTICULARS**

As per PA1077/061/007

#### **5 PHARMACOLOGICAL PROPERTIES**

As per PA1077/061/007

## **6 PHARMACEUTICAL PARTICULARS**

# 6.1 List of excipients

Calcium carbonate
Low-substituted hydroxypropyl cellulose
Aluminium magnesium silicate
Sodium starch glycolate (Type A)
Povidone K30
Saccharin sodium
Magnesium stearate
Blackcurrant flavour

# 6.2 Incompatibilities

Not applicable.

#### 6.3 Shelf life

The shelf life expiry date of this product is the date shown on the container and outer carton of the product as marketed in the country of origin.

## 6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

#### 6.5 Nature and contents of container

Blister packs of 56 chewable/dispersible tablets.

19 May 2023 CRN00DHGR Page 1 of 2

# 6.6 Special precautions for disposal

No special requirements for disposal.

## **7 PARALLEL PRODUCT AUTHORISATION HOLDER**

PCO Manufacturing Ltd.
Unit 10, Ashbourne Business Park
Rath
Ashbourne
Co. Meath
Ireland

## **8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA0465/443/001

## 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 14<sup>th</sup> September 2012

Last updated: April 2016 Last updated: September 2018 Last updated: May 2019

#### 10 DATE OF REVISION OF THE TEXT

May 2023

19 May 2023 CRN00DHGR Page 2 of 2